Entecavir interacts with influx transporters hOAT1, hCNT2, hCNT3, but not with hOCT2: the potential for renal transporter-mediated cytotoxicity and drug-drug interactions

• Main Authors: František eTrejtnar (Author), Jana eMandíková (Author), Marie eVolková (Author), Petr ePávek (Author), Lucie eNavrátilová (Author), Lucie eHyršová (Author), Zlatko eJaneba (Author), Jan ePavlík (Author), Pavel eBárta (Author)
• Format: Book
• Published: Frontiers Media S.A., 2016-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Entecavir (ETV) is one of the most potent agents for the treatment of the hepatitis B viral infection. The drug is principally eliminated by the kidney. The goal of this study was to investigate the potential of ETV to interact in vitro with the renal SLC transporters hOAT1, hOCT2, hCNT2 and hCNT3....